Publications

Opinion: Recent Precedent Shows Overseas Biosimilars Companies Can Be Sued in US

Author, BioSpace

Mark Deming, Hatch-Waxman & Biologics Vice Chair, discusses the recent court decisions that could make foreign biosimilar drug companies more vulnerable to lawsuits in the U.S.